Blocking a Scar Protein Kept Mouse Hearts Pumping After Heart Attack

The trouble is excess. Too much scar tissue makes the heart stiff and less effective at pumping. Over time, that extra material can push a patient toward heart failure, even after the immediate emergency has passed. Heart failure means the organ can no longer move enough blood around the body. Patients become breathless, unusually tired, or develop swollen legs.

What did the experiments show?

Working in mice, the researchers reduced AEBP1 in the cells responsible for scarring after heart attack-like injury. Four weeks on, those mice showed better heart function than animals whose protein levels were left alone.

Timing turned out to be decisive. When the team lowered AEBP1 only after heart failure was already well established, the treatment did nothing for pumping ability. In plain terms, the approach looks better at preventing damage than repairing it.

The researchers then moved to human tissue. In heart samples from heart failure patients kept alive in the lab, dialing down AEBP1 reduced signs of scarring and made the arrangement of heart cells look healthier.

How close is this to a treatment?

Not close. The researchers have not shown that blocking AEBP1 safely prevents heart failure in living patients. The strongest evidence so far comes from mice and lab-maintained human tissue samples, and clinical studies will be needed to establish whether the approach actually improves patients' health.

There's also a timing puzzle to solve. Any future therapy would need to protect normal healing while limiting harmful extra tissue. Stopping the repair process too early could weaken an injured heart that still needs structural support.

What's the takeaway?

The study offers encouraging evidence that heavy scarring is not simply an unavoidable consequence of heart injury. But a medicine based on this finding remains, for now, a research goal rather than a reality.